COLUMVI

Product Overview

About COLUMVI

COLUMVI is a prescription medication containing the active ingredient GLOFITAMAB. It is used to treat certain types of cancer, including follicular lymphoma and marginal zone lymphoma. GLOFITAMAB is a monoclonal antibody that targets CD20, a protein found on the surface of B cells, helping to slow or stop the growth of cancer cells.

Key Benefits & Uses

• Treatment of follicular lymphoma
• Treatment of marginal zone lymphoma
• Monotherapy for patients with follicular lymphoma and marginal zone lymphoma who have received at least two prior therapies

Active Ingredient & Action

GLOFITAMAB works by binding to CD20 on the surface of B cells, marking them for destruction by the immune system. This helps to reduce the number of cancer cells in the body and slow the progression of the disease.

Important Notes

COLUMVI is available by prescription only and should be used under the guidance of a qualified healthcare professional. Patients with a history of severe infusion reactions or hypersensitivity to GLOFITAMAB should not receive COLUMVI. Common side effects include infusion reactions, fatigue, and nausea.